p.44 抽出テキスト

national Observational CLARIFY Registry. JAMA Intern Med 2014; 174: 1651-1659. PMID: 25110899 149. Al-Lamee R, Thompson D, Dehbi HM, et al. ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391: 31-40. PMID: 29103656 150. Al-Lamee R, Howard JP, Shun-Shin MJ, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease: Physiology-Stratified Analysis of ORBITA. Circulation 2018; 138: 1780-1792. PMID: 29789302 151. Weintraub WS, Spertus JA, Kolm P, et al. COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008; 359: 677-687. PMID: 18703470 152. Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. JAMA 2014; 312: 1295-1296. PMID: 25268434 153. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; 2: 1173-1180. PMID: 6128492 154. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation 1982; 66: 14-22. PMID: 6979435 155. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570. PMID: 7914958 156. Bittl JA, He Y, Jacobs AK, et al. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013; 127: 2177-2185. PMID: 23674397 157. Lee PH, Ahn JM, Chang M, et al. Left Main Coronary Artery Disease: Secular Trends in Patient Characteristics, Treatments, and Outcomes. J Am Coll Cardiol 2016; 68: 1233-1246. PMID: 27609687 158. Bainey KR, Alemayehu W, Welsh RC, et al. Long-Term Clinical Outcomes Following Revascularization in High-Risk Coronary Anatomy Patients With Stable Ischemic Heart Disease. J Am Heart Assoc 2021; 10: e018104. PMID: 33342230 159. Shoaib A, Rashid M, Kontopantelis E, et al. Clinical Characteristics and Outcomes From Percutaneous Coronary Intervention of Last Remaining Coronary Artery: An Analysis From the British Cardiovascular Intervention Society Database. Circ Cardiovasc Interv 2020; 13: e009049. PMID: 32873051 160. Faridi KF, Rymer JA, Rao SV, et al. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. Am Heart J 2019; 216: 53-61. PMID: 31401443 161. Kim YH, Park DW, Ahn JM, et al. Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients. EuroIntervention 2013; 9: 110-117. PMID: 23685299 162. Toyota T, Morimoto T, Shiomi H, et al. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Ad hoc vs. Non-ad hoc Percutaneous Coronary Intervention Strategies in Patients With Stable Coronary Artery Disease. Circ J 2017; 81: 458-467. PMID: 28179612 163. Blankenship JC, Gigliotti OS, Feldman DN, et al. Ad hoc percutaneous coronary intervention: A consensus statement from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 81: 748-758. PMID: 23197438 164. Adele C, Vaitkus PT, Wells SK, et al. Cost advantages of an ad hoc angioplasty strategy. J Am Coll Cardiol 1998; 31: 321-325. PMID: 9462574 165. Le Feuvre C, Helft G, Beygui F, et al. Safety, efficacy, and cost advantages of combined coronary angiography and angioplasty. J Interv Cardiol 2003; 16: 195-199. PMID: 12800396 166. Nallamothu BK, Krumholz HM. Putting ad hoc PCI on pause. JAMA 2010; 304: 2059-2060. PMID: 21063016 166a. Maddox TM, Chan PS, Spertus JA, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: Insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2014; 63: 539-546. PMID: 24184238 167. Bangalore S, Maron DJ, Stone GW, et al. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation 2020; 142: 841-857. PMID: 32794407 168. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/

AATS/PCNA/SCAI/STS Guideline for the diagnosis and manage- ment of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60: e44-e164. PMID: 23182125 169. Chen HY, Saczynski JS, Lapane KL, et al. Adherence to evi-

dence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review. Heart Lung 2015; 44: 299-308. PMID: 25766041 170. Patterson T, McConkey HZR, Ahmed-Jushuf F, et al. Long-Term Outcomes Following Heart Team Revascularization Recommendations in Complex Coronary Artery Disease. J Am Heart Assoc 2019; 8: e011279. PMID: 30943827 171. Domienik-Karłowicz J, Kupczyńska K, Michalski B, et al. Fourth universal definition of myocardial infarction. Selected messages from the European Society of Cardiology document and lessons learned from the new guidelines on ST-segment elevation myocardial infarction and non-ST-segment elevation-acute coronary syndrome. Cardiol J 2021; 28: 195-201. PMID: 33843035 172. 日本循環器学会.2020年 JCS ガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法.https://www.j-circ. or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf 173. Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina: A comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol 2013; 62: 1144-1153. PMID: 23916938 174. Robertson RM, Wood AJ, Vaughn WK, et al. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982; 65: 281-285. PMID: 6797752 175. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 2000; 101: 1102-1108. PMID: 10715255 176. Endo A, Kohsaka S, Miyata H, et al. Disparity in the application of guideline-based medical therapy after percutaneous coronary intervention: Analysis from the Japanese prospective multicenter registry. Am J Cardiovasc Drugs 2013; 13: 103-112. PMID: 23585142 177. Nakao K, Yasuda S, Nishimura K, et al. Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study. J Am Heart Assoc 2019; 8: e009692. PMID: 30909774 178. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: A meta-analysis. Am J Med 2009; 122: 356-365. PMID: 19332231 179. Bangalore S, Steg G, Deedwania P, et al. REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340- 1349. PMID: 23032550 180. Baigent C, Blackwell L, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681. PMID: 21067804 181. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504. PMID: 15007110 182. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082-e1143. PMID: 30586774 183. Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018: CD012502. PMID: 30480766 184. Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020: CD011748. PMID: 33078867 185. Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation 2018; 137: 1997-2009. PMID: 29735587 186. Saito Y, Okada S, Ogawa H, et al. JPAD Trial Investigators. Low-

Dose Aspirin for Primary Prevention of Cardiovascular Events in